Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007890-197007000-00008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LINC01322 may serve as a potential diagnostic marker for advanced stage tumors in renal cell carcinoma patients eligible for total nephrectomy.
Biochem Biophys Rep
December 2024
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Renal cell carcinoma (RCC) is a common urological cancer globally and shows a favorable prognosis in early stages of the tumor progression. Due to the poor prognosis for metastatic RCC patients, it is crucial to explore the molecular biology of RCC progression to establish efficient diagnostic and therapeutic markers for these patients. Long non-coding RNAs (lncRNAs) have critical roles in regulation of tumor cell proliferation, migration, and apoptosis during RCC progression.
View Article and Find Full Text PDFNocardiosis in Renal Allograft Recipients.
J Glob Infect Dis
December 2024
Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India.
Introduction: The aim of the study was to study the clinical profile and outcomes of nocardiosis in renal allograft recipients.
Methods: This was a retrospective study of clinical outcomes in consecutive renal allograft recipients with infection over a 22-year period (2000-2022) from a tertiary care center in Southern India. The clinical data were obtained from electronic medical records and patient files.
Evaluation of donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA.
Front Immunol
January 2025
Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.
Background: Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker for detecting graft injury in solid organ transplant recipients. Elevated dd-cfDNA levels are strongly associated with rejection and graft injury, especially antibody-mediated rejection (ABMR). While donor-specific antibodies (dnDSA) are crucial in ABMR, the relationship between dd-cfDNA levels and dnDSA features, such as DSA category, MFI and HLA target loci, remains unclear.
View Article and Find Full Text PDFKidney Biopsy-Proven Diabetic and Non-Diabetic Kidney Diseases and Outcomes in Patients With Type 2 Diabetes Receiving Dialysis: The REIN Registry.
Kidney Med
February 2025
AURAL Strasbourg, Renal Research Division, 5 rue Henri Bergson, 67200 Strasbourg, France.
Rationale & Objective: Chronic kidney disease (CKD) in patients with diabetes does not always equate to diabetic kidney disease (DKD). This study aims to delineate and compare the clinical characteristics, survival rates, and access to kidney transplantation among patients with type 2 diabetes commencing dialysis, who were classified by kidney biopsy as having either DKD or non-diabetic kidney disease (non-DKD).
Study Design: We used the comprehensive French Renal Epidemiology and Information Network registry to analyze baseline clinical characteristics at dialysis inception and outcomes defined as death and access to kidney transplantation.
Senotherapy: Implications for Transplantation.
Transplantation
January 2025
Interdisciplinary Transplantation, Children's Hospital, Hannover Medical School, Hannover, Germany.
Cellular senescence has been identified as a potential driver of age-associated loss of organ function and as a mediator of age-related disease. Novel strategies in targeting senescent cells have shown promise in several organ systems to counteract functional decline, chronic inflammation, and age-dependent loss of repair capacity. Transgenic models have provided proof of principle that senolysis, the elimination of senescent cells, is an attractive strategy to overcome many age-related pathologies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!